아밀로이드증 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)
Amyloidosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
상품코드:1706767
리서치사:Transparency Market Research
발행일:2025년 02월
페이지 정보:영문 198 Pages
라이선스 & 가격 (부가세 별도)
한글목차
아밀로이드증 치료제 시장 - 연구 범위
TMR의 보고서 "세계 아밀로이드증 치료제 시장"은 2025-2035년의 예측 기간 중 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2019-2035년의 세계 아밀로이드증 치료제 시장의 매출과 예측을 제공하기 위해 2025년을 기준 연도로, 2035년을 예측연도로 설정했습니다. 또한 2025-2035년 세계 아밀로이드증 치료제 시장의 연평균 성장률(CAGR%)을 제시합니다.
이 보고서는 광범위한 1차 연구를 통해 작성되었으며, 분석가들은 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 문서 등을 참조하여 아밀로이드증 치료제 시장을 추론했습니다. 아밀로이드증 치료제 시장을 추론했습니다.
시장 현황
2024년 시장 규모
27억 달러
2035년 시장 규모
63억 달러
CAGR
8.2%
이 보고서는 세계 아밀로이드증 치료제 시장의 경쟁 환경을 조사했습니다. 세계 아밀로이드증 치료제 시장에서 활동하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성별로 프로파일링되어 있습니다. 기업 개요, 재무 상태, 최근 동향, SWOT는 세계 아밀로이드증 치료제 시장의 기업이 이 보고서에서 소개하는 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 개요 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계의 아밀로이드증 치료제 시장의 시장 분석과 예측, 2020-2035년
제5장 주요 인사이트
주요 업계 이벤트(파트너십, 협업, 합병, 인수 등)
기술적 진보
최종사용자에서의 주요 구입 지표
Porter's Five Forces 분석
PESTEL 분석
주요 국가·지역별 규제 시나리오
가격 동향
밸류체인 분석
지역별/세계별 상환 시나리오
주요 브랜드/제품 분석
제6장 세계의 시장 분석과 예측 : 약제 유형별
서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 유형별, 2020-2035년
모노클로널 항체
프로테아좀 저해제
면역 조절제
코르티코스테로이드
알킬화제
트란스사이레틴 안정제
기타
의약품 유형별 시장의 매력
제7장 세계의 시장 분석과 예측 : 적응증별
서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 적응증별, 2020-2035년
AL(원발성) 아밀로이드증
AA(2차성) 아밀로이드증
가족성 ATTR 아밀로이드증
적응증별 시장의 매력
제8장 세계의 시장 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/진전
시장 금액 예측 : 유통 채널별, 2020-2035년
병원 약국
소매 약국
온라인 약국
유통 채널별 시장의 매력
제9장 세계의 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
국가·지역별 시장의 매력
제10장 북미의 시장 분석과 예측
미국
캐나다
제11장 유럽의 시장 분석과 예측
독일
영국
프랑스
이탈리아
스페인
기타 유럽 지역
제12장 아시아태평양의 시장 분석과 예측
중국
일본
인도
한국
호주와 뉴질랜드
기타 아시아태평양
제13장 라틴아메리카의 시장 분석과 예측
브라질
멕시코
기타 라틴아메리카 지역
제14장 중동 및 아프리카의 시장 분석과 예측
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
제15장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 기업별(2024)
기업 개요
Pfizer Inc.
Johnson & Johnson Services, Inc.
GSK plc
Takeda Pharmaceutical Company Limited
Amgen Inc.
Bristol-Myers Squibb Company
Alnylam Pharmaceuticals, Inc.
AstraZeneca
BridgeBio Inc.
Ionis Pharmaceuticals
Attralus, Inc.
Eisai Co., Ltd.
Other Prominent Players
KSA
영문 목차
영문목차
Amyloidosis Therapeutics Market - Scope of Report
TMR's report on the global amyloidosis therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global amyloidosis therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global amyloidosis therapeutics market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the amyloidosis therapeutics market.
Market Snapshot
Market Value in 2024
US$ 2.7 Bn
Market Value in 2035
US$ 6.3 Bn
CAGR
8.2%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global amyloidosis therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global amyloidosis therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global amyloidosis therapeutics market.
The report delves into the competitive landscape of the global amyloidosis therapeutics market. Key players operating in the global amyloidosis therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global amyloidosis therapeutics market profiled in this report.
Key Questions Answered in Global amyloidosis therapeutics Market Report:
What is the sales/revenue generated by amyloidosis therapeutics across all regions during the forecast period?
What are the opportunities in the global amyloidosis therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Amyloidosis Therapeutics Market - Research Objectives and Research Approach
The comprehensive report on the global amyloidosis therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global amyloidosis therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global amyloidosis therapeutics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Amyloidosis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Amyloidosis Therapeutics Market Analysis and Forecasts, 2020-2035
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events (Partnerships, Collaborations, Mergers, Acquisitions, etc.)
5.2. Technological Advancements
5.3. Key Purchase Metrics for End-Users
5.4. PORTER's Five Forces Analysis
5.5. PESTLE Analysis
5.6. Regulatory Scenario by Key Countries/Regions
5.7. Pricing Trends
5.8. Value Chain Analysis
5.9. Reimbursement Scenario by Region/globally
5.10. Key Brand/Product Analysis
6. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type, 2020-2035
6.3.1. Monoclonal Antibodies
6.3.2. Proteasome Inhibitors
6.3.3. Immunomodulator
6.3.4. Corticosteroids
6.3.5. Alkylating Agents
6.3.6. Transthyretin stabilizers
6.3.7. Others
6.4. Market Attractiveness By Drug Type
7. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2020-2035
7.3.1. AL (Primary) Amyloidosis
7.3.2. AA (Secondary) Amyloidosis
7.3.3. Familial ATTR Amyloidosis
7.4. Market Attractiveness By Indication
8. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2020-2035
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel
9. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Amyloidosis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2020-2035
10.2.1. Monoclonal Antibodies
10.2.2. Proteasome Inhibitors
10.2.3. Immunomodulator
10.2.4. Corticosteroids
10.2.5. Alkylating Agents
10.2.6. Transthyretin stabilizers
10.2.7. Others
10.3. Market Value Forecast By Indication, 2020-2035
10.3.1. AL (Primary) Amyloidosis
10.3.2. AA (Secondary) Amyloidosis
10.3.3. Familial ATTR Amyloidosis
10.4. Market Value Forecast By Distribution Channel, 2020-2035
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast By Country, 2020-2035
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Indication
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Amyloidosis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2020-2035
11.2.1. Monoclonal Antibodies
11.2.2. Proteasome Inhibitors
11.2.3. Immunomodulator
11.2.4. Corticosteroids
11.2.5. Alkylating Agents
11.2.6. Transthyretin stabilizers
11.2.7. Others
11.3. Market Value Forecast By Indication, 2020-2035
11.3.1. AL (Primary) Amyloidosis
11.3.2. AA (Secondary) Amyloidosis
11.3.3. Familial ATTR Amyloidosis
11.4. Market Value Forecast By Distribution Channel, 2020-2035
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast By Country/Sub-region, 2020-2035
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Indication
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Amyloidosis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020-2035
12.2.1. Monoclonal Antibodies
12.2.2. Proteasome Inhibitors
12.2.3. Immunomodulator
12.2.4. Corticosteroids
12.2.5. Alkylating Agents
12.2.6. Transthyretin stabilizers
12.2.7. Others
12.3. Market Value Forecast By Indication, 2020-2035
12.3.1. AL (Primary) Amyloidosis
12.3.2. AA (Secondary) Amyloidosis
12.3.3. Familial ATTR Amyloidosis
12.4. Market Value Forecast By Distribution Channel, 2020-2035
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast By Country/Sub-region, 2020-2035
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. South Korea
12.5.5. Australia & New Zealand
12.5.6. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Indication
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Amyloidosis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020-2035
13.2.1. Monoclonal Antibodies
13.2.2. Proteasome Inhibitors
13.2.3. Immunomodulator
13.2.4. Corticosteroids
13.2.5. Alkylating Agents
13.2.6. Transthyretin stabilizers
13.2.7. Others
13.3. Market Value Forecast By Indication, 2020-2035
13.3.1. AL (Primary) Amyloidosis
13.3.2. AA (Secondary) Amyloidosis
13.3.3. Familial ATTR Amyloidosis
13.4. Market Value Forecast By Distribution Channel, 2020-2035
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country/Sub-region, 2020-2035
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Indication
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Amyloidosis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020-2035
14.2.1. Monoclonal Antibodies
14.2.2. Proteasome Inhibitors
14.2.3. Immunomodulator
14.2.4. Corticosteroids
14.2.5. Alkylating Agents
14.2.6. Transthyretin stabilizers
14.2.7. Others
14.3. Market Value Forecast By Indication, 2020-2035
14.3.1. AL (Primary) Amyloidosis
14.3.2. AA (Secondary) Amyloidosis
14.3.3. Familial ATTR Amyloidosis
14.4. Market Value Forecast By Distribution Channel, 2020-2035
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast By Country/Sub-region, 2020-2035
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Type
14.6.2. By Indication
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
